A. Jon Stoessl, M.D., Chair
A. Jon Stoessl is Professor & Head of Neurology and Co-Director of the Djavad Mowafaghian Centre for Brain Health at UBC & Vancouver Coastal Health.
Dr. Stoessl holds a Tier 1 Canada Research Chair in Parkinson's, was previously the Director of the Pacific Parkinson's Research Centre and Parkinson's Foundation Centre of Excellence at UBC. Dr. Stoessl is Deputy Editor of the Movement Disorders Journal and sits on the editorial boards of Lancet Neurology, Journal of Parkinson's Disease, Parkinsonism & Related Disorders and Translational Neurodegeneration. He has served on numerous scientific advisory boards and is the past Chair of the Scientific Advisory Boards of the Parkinson Society of Canada and Ontario Mental Health Foundation as well as the Interdisciplinary Adjudication Committee of the Canada Research Chairs program and the Mentoring Committee of the Parkinson Study Group. He serves on the Board of the International Association of Parkinsonism & Related Disorders, co-chairs the Steering Committee for the World Parkinson Congress, is President-Elect of the World Parkinson Coalition, previously served on the International Executive Committee of the Movement Disorders Society and chaired the MDS Awards Committee. He is a Member of the Order of Canada and a Fellow of the Canadian Academy of Health Sciences. He was Chair of the Local Organizing Committee and Co-Chair of the Congress Scientific Program Committee for the recent (2017) MDS Vancouver Congress. Dr. Stoessl's research involves the use of positron emission tomography to study Parkinson's disease and related disorders, including the use of imaging as a biomarker, the basis for complications of treatment and mechanisms of the placebo effect.
Timothy Greenamyre, M.D., Ph.D., Co-Chair
Dr. Tim Greenamyre is the Love Family Professor and vice-chair of neurology, chief of Movement Disorders, and director of the Pittsburgh Institute for Neurodegenerative Diseases (PIND) and the American Parkinson Disease Association Advanced Center for Parkinson’s Disease Research at the University of Pittsburgh.
Dr. Greenamyre is a member of the Scientific Advisory Board of the Michael J. Fox Foundation, and a member of the scientific advisory boards of the Parkinson’s Foundation and the American Parkinson Disease Association. He has been listed as one of the ‘Best Doctors in America’ since the mid-1990s. He is editor-in-chief of the scientific journal Neurobiology of Disease. His laboratory studies mechanisms of neurodegeneration in Parkinson’s disease, with a focus on gene-environment interactions. Translational studies use pharmacological and ‘gene therapy’ approaches.
Roy Alcalay, M.D., M.S.
Dr. Roy Alcalay is an Assistant Professor of Neurology at the Taub Institute and the program director of the Movement Disorders Fellowship at the Columbia University Medical Center, a Center of Excellence.
Dr. Alcalay's primary research work involves the genetics and the epidemiology of Parkinson's. He is also a member of the American Academy of Neurology and of the Movement Disorder Society. Dr. Alcalay has contributed to a range of original articles in leading medical research journals, including the The New England Journal of Medicine, Neurology, Archives of Neurology, Genetics in Medicine, Journal of Clinical and Experimental Neuropsychology, Movement Disorders and Parkinsonism and Related Disorders.
Dr. Alcalay received his medical degree from Tel Aviv University, Israel, his neurology training from the Harvard University residency program at Massachusetts General Hospital and Brigham and Women's Hospital and his movement disorders training at Columbia University. He is a graduate of the Patient Oriented Research and earned Master's in biostatistics from Columbia University.
Robert Edwards, M.D.
Dr. Robert Edwards is the Cahill Professor of Neurology and Physiology at the University of California, San Francisco (UCSF), a Center of Excellence.
Dr. Robert Edwards is a neuroscientist recognized for his work on the molecular and cellular basis of neurotransmitter release. He is particularly known for identification of the proteins that transport classical transmitters into neurosecretory vesicles, and for his work on their mechanism, regulation and physiological roles. His work now extends to the phenomena of neurotransmitter corelease, dense core vesicle formation, and the function of A protein in the human brain that is associated with the development of Parkinson’s. It is the main component of Lewy bodies., a presynaptic protein with a central role in Parkinson’s disease.
Dr. Robert Edwards was born in New York City, attended Yale College and Johns Hopkins Medical School. He trained in clinical neurology, studied as a postdoctoral fellow with William J. Rutter at UCSF and joined the faculty at UCLA in 1990 before returning to UCSF in 1995. He is a member of the National Academy of Medicine and the National Academy of Sciences.
Jennifer Goldman, M.D., M.S.
Dr. Jennifer Goldman is an Associate Professor in the Department of Neurological Sciences at Rush University, a Center of Excellence.
Dr. Goldman's clinical and research work focuses on understanding and improving treatments for cognitive and behavioral features of Parkinson's, parkinsonian disorders, A progressive, neurodegenerative disease that shares symptoms of both Alzheimer’s disease and Parkinson’s. Unlike Parkinson’s disease dementia, cognitive symptoms are present before or within one year of noticing movement symptoms. The central features of DLB include progressive cognitive decline, changes in alertness and attention, visual hallucinations and parkinsonian motor symptoms such as slowness of movement, difficulty walking or rigidity., and other movement disorders using advanced neuroimaging, genetics and other biomarkers. She is board certified by the American Board of Neurology and Psychiatry. As a movement disorder specialist, Goldman treats patients with PD, A group of brain disorders that initially look like Parkinson's disease, but differ in the course of the disease and response to antiparkinson medications. The term is used interchangeably with Parkinson-plus syndromes. disorders, dementia with Lewy bodies, A disorder in which muscles contract uncontrollably, causing abnormal movements and postures; can be very painful., and other movement-related conditions in the clinic. She directs the cognitive-behavioral program within the Section of Movement Disorders. She was the 2013 recipient of the Rush University Faculty Award for Excellence in Education and has lectured nationally and internationally. She serves on the AAN Education Committee, MDS Leadership Task Force and as chair of the MDS Pan-American Section Education Committee.
Dr. Goldman graduated from Princeton University and received her M.D. from Northwestern University Medical School. She completed her neurology residency training at Washington University in St. Louis, followed by a movement disorder fellowship and a Master of Science degree in clinical research at Rush University in Chicago.
Matthew LaVoie, Ph.D.
Dr. Matthew LaVoie is an Associate Professor of Neurology at Brigham and Women's Hospital and Harvard Medical School.
Dr. LaVoie's lab is dedicated to uncovering the early molecular events responsible for the selective neurodegeneration and unique neuropathology associated with Parkinson's disease. A major goal of the lab is to understand the basic physiological functions of genes associated with familial Parkinson's, and the impact of their pathogenic mutations. Dr. LaVoie serves on the Scientific Advisory Board for the Parkinson's Foundation and the National Scientific Advisory Council for the American Foundation for Aging Research. He served on the Editorial Board of the Journal of Biological Chemistry and is currently the Editor-in-Chief of Brain Research. In addition to his responsibilities as Principal Investigator of a basic research laboratory at the Brigham, Dr. LaVoie was the co-founder and co-director (with Dr. Barbara Bierer) of the Brigham Research Leadership Program and founder of the Career Building at a Research Hospital seminar series.
Dr. LaVoie received his B.A. and B.S. in Biology and Psychology from Rutgers University and his Ph.D. from the University of Pittsburgh.
Laura Marsh, M.D.
Dr. Laura Marsh is a Professor in the Menninger Department of Psychiatry at Baylor College of Medicine, a Center of Excellence.
Dr. Marsh is a geriatric neuropsychiatrist and her clinical and research expertise focuses on the recognition and treatment of psychiatric disturbances in patients with Parkinson's. Since 2009, she has been the Executive Director of the Mental Health Service at the Michael E. DeBakey Veterans Affairs Medical Center. Previously, she was director and principal investigator of the Clinical Research Program of the NIH-funded Morris K. Udall Parkinson's Disease Research Center at Johns Hopkins University School of Medicine. In addition to her efforts to improve psychiatric treatments for people with Parkinson's, a focus of her administrative role is to facilitate the general integration of psychiatric and mental health care into medical care and to promote positive attitudes and beliefs about mental health care and psychiatric illnesses. She is an active member of the American Association of Geriatric Psychiatry, the Parkinson's Study Group and the Movement Disorders Society and has published widely on psychiatric disorders in PD and related conditions, including as co-editor of the book, Psychiatric Issues in Parkinson's Disease: A Practical Guide.
Dr. Marsh received her B.A. from Oberlin College and her M.D. from Ohio State College of Medicine. She completed her residency at Johns Hopkins University School of Medicine.
Ian Reynolds, Ph.D.
Dr. Ian Reynolds is the Vice President and Head of Discovery for Global Research and Development at Teva Pharmaceuticals.
Dr. Reynolds' interests are focused on drug discovery for neurological and neurodegenerative diseases. He currently leads the CNS Discovery group at Teva Pharmaceuticals in the Greater Philadelphia area. At Knopp, he led the team investigating the mechanism of action of dexpramipexole, which was in development for disease modification in amyotrophic lateral sclerosis (ALS). In that position, Dr. Reynolds ran the biology group that was working on dexpramipexole, as well as other CNS targets. At Merck, he was responsible for drug discovery groups working on Parkinson's, stroke, A neurodegenerative disorder that results in loss of memory, thinking and language skills and behavioral changes. It is the most common form of dementia. and ophthalmology. Dr. Reynolds has extensive experience in academic research focused on neurodegenerative disease, including Parkinson's and stroke. The academic expertise includes substantial time leading and administering graduate education in pharmacology and neuroscience.
Dr. Reynolds received his B.Sc. from the University of Leeds, his Ph.D. from the Johns Hopkins University School of Medicine and completed his post-doctoral fellowship in Neuropharmacology at the University of Chicago.
Margaret Rice, Ph.D.
Dr. Margaret Rice is a Professor in the Department of Neurosurgery and the Department of Neuroscience and Physiology at New York University School of Medicine, a Center of Excellence.
Dr. Rice's research in her laboratory is focused on regulation of A chemical messenger (neurotransmitter) that regulates movement and emotions., a key transmitter in motor and reward pathways in the brain. The Rice group uses carbon-fiber microelectrodes with fast-scan cyclic voltammetry to provide real-time monitoring of axonal dopamine release in dorsal and ventral striatum and somatodendritic release in the substantia nigra and ventral tegmental area, primarily in brain slices. Current research is centered on a novel finding from the Rice group that hydrogen peroxide (H2O2), produced by mitochondrial respiration, is an Caused by factors within the body or mind, rather than by external factors. For example, endogenous depression is caused by processes in the brain rather than external circumstances. regulator of synaptic and somatodendritic dopamine release, as well as dopamine neuron activity in the substantia nigra. In addition to this core project, the Rice group also studies regulation of axonal dopamine release by glutamate, A chemical messenger (neurotransmitter) involved in muscle relaxation, sleep, diminished emotional reaction and sedation., calcium, cannabinoids and caffeine, the mechanism and regulation of somatodendritic dopamine release and dopamine dysfunction in transgenic mouse models of dystonia and PD.
Dr. Rice received her B.S from the University of Oklahoma and her Ph.D. from the University of Kansas. Her post-doctoral training was done at NYU School of Medicine.
Stephen Shea, Ph.D.
Dr. Stephen Shea is an Associate Professor at Cold Spring Harbor Laboratory.
Dr. Shea's lab studies the neural circuitry underlying social communication and decisions. He uses natural social communication behavior in mice as a model to understand circuits and processes that are evolutionarily conserved and therefore shared broadly across species, likely contributing to disorders such as autism. Shea and colleagues have examined how emotion and arousal enable mice, via their olfactory systems, to store memories of other individuals and of related social signals. Recently, the lab made a key breakthrough, developing the ability to record from GCs in awake animals and discovering that their activity is dramatically modulated by state of consciousness. Finally, the Shea lab completed a series of studies of a different form of social recognition: auditory recognition of pup vocalizations by their mothers. Through this research, they have shown that a mouse model of Rett syndrome exhibits deficits in communication and learning not unlike those in human patients.
Dr. Shea received his B.S. from the University of Maryland College Park and his Ph.D. from the University of Chicago.
Richard Smeyne, Ph.D.
Dr. Richard Smeyne is a Professor in the Jack and Vickie Farber Institute for Neuroscience at Thomas Jefferson University.
Dr. Smeyne's research focuses on the cell biology of Parkinson's, with an interest in the interactions between the immune system and the central nervous system (brain and spinal cord). His lab is also studying which cells (neurons and/or glia) are responsible for the toxicity seen following MPTP administration. Additionally, Dr. Smeyne studies the role of environmental enrichment in neuroprotection. He has published in high-impact journals including Nature, Science, Proceedings of the National Academy of Sciences, Cell and the Journal of Neuroscience.
Dr. Smeyne received his doctorate in anatomy from Thomas Jefferson University and completed his postdoctoral training in molecular biology at the Roche Institute of Molecular Biology.